Dr. George Allen is an Associate Professor and Chair of the Department of Pharmacy Practice at the College of Pharmacy at UNE. Dr. Allen earned his Doctor of Pharmacy degree from the Massachusetts College of Pharmacy and Allied Health Sciences in 1998. Dr. Allen then completed a Pharmacy Practice Residency at the University of Washington in Seattle, WA, and a Fellowship in Infectious Diseases Pharmacotherapy at Wayne State University in Detroit, MI. As a postdoctoral fellow, Dr. Allen performed laboratory-based research examining induction of bacterial resistance by a variety of antimicrobials. Before joining UNE in 2010, Dr. Allen was a member of the faculty at the Oregon State University College of Pharmacy in Portland, OR, where he continued his in vitro research and participated in didactic and experiential education of Doctor of Pharmacy students.
Massachusetts College of Pharmacy and Allied Health Sciences
University of New Hampshire
Infectious Diseases Pharmacotherapy
Wayne State University College of Pharmacy and Allied Health
University of Washington and Harborview Medical Centers
Pharmacotherapy of infectious diseases
Dr. Allen's research focuses on investigations of the pharmacodynamics of antimicrobial resistance. He uses in vitro modeling techniques that allow evaluation of the effects of varying antimicrobial exposures on the development of resistance. The majority of Dr. Allen's current work consists of studies of two unique measures of antimicrobial activity, the mutant prevention concentration and mutant selection window. This work is performed using a variety of microorganisms, including Acinetobacter baumannii, enterococci, Neisseria gonorrhoeae, Salmonella Typhi, and methicillin-resistant Staphylococcus aureus, with most research focusing on the fluoroquinolone antimicrobials. Broadly speaking, Dr. Allen's work is designed to determine those antimicrobials (as well as the optimal doses of said antimicrobials) that will best prevent the emergence of bacterial resistance in the laboratory and in clinical settings.
Antimicrobial pharmacodynamics and pharmacokinetics
Allen GP, Deshpande LM. Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin, and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 2010;35:45-9.
Allen GP, Hankins CD. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy 2009;64:359-63.
Allen GP, Bierman BC. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and _resistant Enterococcus faecalis and Enterococcus faecium. International Journal of Antimicrobial Agents 2009;34:21-4.
McGregor JC, Allen GP, Bearden DT. Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Therapeutics and Clinical Risk Management 2008;4:843-53.
Bearden DT, Allen GP, Christensen JM. Comparative in vitro activities of topical wound care products against community-associated methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 2008;62:769-72.
Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. International Journal of Antimicrobial Agents 2004;24:150-60.
Bearden DT, Allen GP. Impact of antimicrobial control programs on patient outcomes: pharmacy perspective. Disease Management and Health Outcomes 2003;11:723-36.
Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 2003;47:2606-14.
Allen GP. The mutant prevention concentration: a review. Journal of Infectious Diseases Pharmacotherapy 2003;6:27-47.
Allen GP, Cha RC, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 2002;46:2606-12.